BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co OCF/Debt

The Operating Cash Flow to Debt Ratio of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 23.42 %. In the previous year, Operating Cash Flow to Debt Ratio was 15.69 % — a change of 49.29% (higher).

OCF/Debt

23.42 %

YoY

49.29%

Last updated:

Operating Cash Flow to Debt Ratio of BrightGene Bio-Medical Technology Co is 2025 23.42 % . Operating Cash Flow to Debt Ratio of BrightGene Bio-Medical Technology Co was 2024 15.69 % . It decreases by 49.29% higher compared to the previous year.

The BrightGene Bio-Medical Technology Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2020
200.52 CNY
Jan 1, 2021
28.46 CNY
Jan 1, 2022
19.75 CNY
Jan 1, 2023
12.06 CNY
Jan 1, 2024
15.69 CNY
Jan 1, 2025
23.42 CNY
The BrightGene Bio-Medical Technology Co OCF/Debt history
YEAROCF/DebtYoY
23.42 %+49.29%
15.69 %+30.08%
12.06 %-38.93%
19.75 %-30.61%
28.46 %-85.81%
200.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Operating Cash Flow to Debt Ratio of BrightGene Bio-Medical Technology Co is 23.42 % in 2025.

Operating Cash Flow to Debt Ratio of BrightGene Bio-Medical Technology Co changed from 15.69 % to 23.42 %, representing a 49.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co